<DOC>
	<DOC>NCT00854308</DOC>
	<brief_summary>This is a Phase II, double-blind, randomized, multicenter trial designed to preliminarily evaluate the activity and safety of treatment with MetMAb + erlotinib versus erlotinib + placebo in second- and third-line Non-Small Cell Lung Cancer (NSCLC). Up to 180 patients will be randomized in a 1:1 ratio to one of the two treatment arms.</brief_summary>
	<brief_title>A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Patients must meet the following criteria for study entry: Histologically confirmed NSCLC Availability of a tumor specimen Recurrent or progressive disease following at least one chemo containing regimen for Stage IIIB/IV disease Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) At least one measurable lesion on a pretreatment 18fluorodeoxyglcoseâˆ’positron emission tomography (FDGPET) scan that is also a target lesion on computed tomography (CT) according to RECIST More than two prior treatments for Stage IIIB/IV More than 30 days of exposure to an investigational or marketed agent that can act by EGFR inhibition, or a known epidermal growth factor receptor (EGFR)related toxicity resulting in dose modifications Chemotherapy, biologic therapy, radiotherapy or investigational drug within 28 days prior to randomization Untreated and/or active (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) central nervous system (CNS) metastasis History of serious systemic disease within the past 6 months prior to randomization Uncontrolled diabetes Major surgical procedure or significant traumatic injury within 28 days prior to randomization Anticipation of need for a major surgical procedure during the course of the study Local palliative radiotherapy within 7 days prior to randomization or persistent adverse effects from radiotherapy that have not been resolved to Grade II or less prior to randomization Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Tarceva</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>